| Authors: |
Carraway HE; Division of Hematologic Oncology and Blood Disorders, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. Electronic address: carrawh@ccf.org., Brunner AM; Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Lai CE; Leukemia Clinical Research Unit, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA., Luskin MR; Division of Leukemia, Dana Farber Cancer Institute, Boston, MA., Park J; Cellular Therapy Service, Deparment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Perl AE; Leukemia Clinical Research Unit, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA., Stein EM; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Zeidan AM; Department of Internal Medicine, Yale University, New Haven, CT., Zeidner JF; Division of Hematology, Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Komrokji R; Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL. |
